Lambda Therapeutic Research proudly announces that its Mehsana facility has achieved NPRA accreditation and its Ahmedabad facility has successfully renewed NPRA accreditation.

Successful NPRA Accreditation for Mehsana & Ahmedabad Facilities

We are proud to share that our Mehsana facility has achieved accreditation by the National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia. The inspection conducted from October 10 to October 13, 2023, has been successfully closed, and the Mehsana facility is now NPRA-approved. This accreditation is valid from July 11, 2024, to July 10, 2027. In addition, our Ahmedabad facility has achieved its 5th consecutive accreditation by the NPRA. The inspection conducted from November 27 to December 1, 2023, has been successfully closed, and the NPRA Malaysia accreditation for the Ahmedabad facility is now valid until April 10, 2027. Having been accredited by the NPRA since 2018, our Ahmedabad facility continues to uphold the highest standards of regulatory excellence, reflecting our ongoing commitment to operational integrity and compliance.

These achievements demonstrate Lambda Therapeutic Research’s unwavering dedication to maintaining top-tier regulatory standards and delivering reliable results for our clients worldwide. As a leading full-service global CRO, Lambda Therapeutic Research remains committed to providing comprehensive, top-tier clinical research services to the global pharmaceutical, biotech, and generic industries.